Filing Flows

Filing Flows › Iovance Biotherapeutics (IOVA) › Next earnings date

Iovance Biotherapeutics (IOVA) earnings: beat the estimate

Iovance Biotherapeutics (IOVA) reported on Nov 5, 2026 and beat the EPS estimate: −$0.05 against −$0.09 (+41.3%). Revenue was $121M for Q3 2026, +80% year over year. It beat the EPS estimate in 60% of the quarters on record.

Last result+41.3% vs estimate
Beat rate60%

The last report

Iovance Biotherapeutics reported revenue of $121M for the third quarter 2026 (+80% Y/Y), net loss $22.3M. How it makes money → · Every quarter →

Iovance Biotherapeutics: EPS against the estimate, last 5 reportsIovance Biotherapeutics: EPS against the estimate, last 5 reportsEstimateReported−$0.26−$0.25Nov 25−$0.18−$0.18Feb 26−$0.15−$0.19May 26−$0.13−$0.11Aug 26−$0.09−$0.05Nov 26
Latest (Nov 26): Estimate −$0.09, Reported −$0.05.
IOVA: the stock's move on each reportIOVA: the stock's move on each reportAug 6, 2026+46.1%May 7, 2026-11.5%Feb 24, 2026+32.5%Nov 6, 2025+27.1%

Iovance Biotherapeutics' latest quarter

Iovance Biotherapeutics, Q3 2026: revenue $121M (+80% year over year), operating margin -19.7%, net loss $22.3M, operating cash flow −$4.5M. The chart follows the revenue to costs, profit and cash.

Questions

Did Iovance Biotherapeutics beat earnings?

Iovance Biotherapeutics (IOVA) reported on Nov 5, 2026 and beat the EPS estimate: −$0.05 against −$0.09 (+41.3%).

When does IOVA report earnings?

The next date is not set yet.

Does Iovance Biotherapeutics usually beat earnings?

It beat the consensus EPS estimate in 60% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.